Alzinova
3,78 SEK -2,58%Vær den første som følger denne virksomhed
Alzinova is a biotechnology company. The company specializes in the therapeutic treatment of Alzheimer's and conducts research and development of peptides that are further developed as vaccines. In addition, the company also develops various research tools in the work area. The largest operations are in the Nordic market. The company was founded in 2011 and is headquartered in Gothenburg.
Omsætning
-
EBIT %
-
P/E
-
Udbytteafkast, %
-
Kursmål
-
Anbefaling
-
Opdateret
-
First North Stockholm
ALZ
Daglig lav / høj pris
3,72 / 3,92
SEK
Markedsværdi
337,05 mio. SEK
Aktieomsætning
705,79 t SEK
Volumen
186 t
Finanskalender
Delårsrapport
14.11.2024
Årsrapport
27.02.2025
Større aktionærerKilde: Millistream Market Data AB
| Ejer | Kapital | Stemmer |
|---|---|---|
| Maida Vale Capital | 15,2 % | 15,2 % |
| Försäkrings AB Avanza Pension | 7,0 % | 7,0 % |
| Nordnet Pensionsförsäkring | 4,2 % | 4,2 % |
| Patrik Ahlvin | 2,3 % | 2,3 % |
| Gjertz, Sara | 1,7 % | 1,7 % |
| Mivac Development | 1,6 % | 1,6 % |
| Özlem Erdogdu Gül | 1,5 % | 1,5 % |
| MGC Capital Ltd | 1,4 % | 1,4 % |
| Moll Invest AB | 1,4 % | 1,4 % |
| Ålandsbanken i ägares ställe | 1,3 % | 1,3 % |
ViserAlle indholdstyper
Alzinova publishes interim report January – June 2024
Status update from Alzinova
Join Inderes community
Don't miss out - create an account and get all the possible benefits
Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools